Repligen Reports Record Quarter, Increases 2020 Guidance
The coronavirus pandemic has done little to hamper the growth trajectory of the bioprocess engineering leader.
Motley Fool · 08/03 18:33
Did Hedge Funds Drop The Ball On Repligen Corporation (RGEN) ?
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional invest
Insider Monkey · 08/03 17:10
Repligen (RGEN) Hits Fresh High: Is There Still Room to Run?
Repligen (RGEN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks · 07/31 13:15
Repligen Corporation's (RGEN) CEO Tony Hunt on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha · 07/31 04:53
Repligen EPS beats by $0.14, beats on revenue
Repligen (NASDAQ:RGEN): Q2 Non-GAAP EPS of $0.42; GAAP EPS of $0.30 beats by $0.14. Revenue of $87.46M (+23.7% Y/Y) beats by $9.07M. Organic Revenue growth
seekingalpha · 07/30 16:33
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29)
Benzinga · 07/30 12:09
Repligen shares are trading higher after the company reported better-than-expected Q2 EPS and sales results. The company also raised its FY20 EPS and sales guidance above analyst estimates.
Benzinga · 07/30 11:51
Repligen Raises FY20 Adj. EPS From $1.09-$1.14 To $1.24-$1.29 vs $1.13 Est., Raises FY20 Sales Guidance From $309M-$319M To $332M-$340M vs $317.04M Est.